Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Dako Launches Two Ready-to-Use Antibodies for Cancer Diagnosis

Published: Wednesday, May 07, 2014
Last Updated: Tuesday, May 06, 2014
Bookmark and Share
Company announces addition of Anti-CK 8/18 and Anti-TdT antibodies for routine diagnostic use.

Dako has announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by pathologists to stain CK 8/18 in tissue samples and thereby help classify tumors of unknown origin. Keratins are one of the most potent epithelial differentiation and tumor markers in cancer diagnostics.

Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in tissue samples. In immunohistochemistry, antibodies to TdT can be used to demonstrate the presence of pre-T and pre-B cells and multipotent hematopoietic stem cells that possess the antigen.

Both Anti-CK 8/18 and Anti-TdT provide excellent specificity and sensitivity and have been reviewed and accepted by key pathology experts. Both antibodies provide optimal staining results enabled by the FLEX Ready-to-Use Dako solutions.

FLEX Ready-to-Use is a plug-and-play solution consisting of pre-diluted antibodies, a visualization system, and optimized validated protocols developed in collaboration with leading pathology experts.

The protocols are developed to take into account pre-analytical variations and different ways of processing and handling tissue samples, ensuring optimal staining results for pathology labs.

"With the FLEX RTU solution, it takes less time for a lab to validate new antibodies for routine diagnostic use," said Hans Christian Pedersen, global product manager, Dako IHC reagents. "FLEX Ready-to-Use antibodies are helping labs get high-quality results from day one."

"We are pleased to add these two high-quality antibodies to our comprehensive offering to pathologists around the world," said Britt Meelby Jensen, vice president of Marketing and Pathology Sales in Agilent's Diagnostics and Genomics business. "One of our goals is to constantly establish new quality benchmarks within IHC reagents."

Both products are available from Dako now as 1.0 mL concentrates and 12 mL (60 tests) FLEX RTUs for Autostainer Link 48.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Recognizes Australian Genome Research Facility as Certified Service Provider
Nonprofit organization offers scientists access to leading-edge technologies.
Saturday, October 31, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Announces Global Distribution Agreement with Cartagenia for CNV Analysis
To assist cytogenetic labs in the clinical interpretation of microarray data.
Friday, May 30, 2014
Agilent Thought Leader Award Supports Metabolic Research
Princeton team developing LC/MS methods, bioinformatics tools for discovery of metabolic regulatory mechanisms.
Tuesday, April 22, 2014
Agilent to Host Young Scientist Forums in Asia Pacific
Events provide platform for rising talents in Australia, Singapore to exchange ideas with leading scientific scholars.
Wednesday, March 26, 2014
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Agilent Awards Grant for Translational Research in Cardiometabolic Disease
Dr. Christopher Newgard's team at Duke University use Agilent platforms to better understand disease mechanisms.
Thursday, January 16, 2014
Agilent Appoints Senior VP and President of Life Sciences and Diagnostics Group
Fred Strohmeier, has been named senior vice president, Agilent, and president of Agilent's Life Sciences and Diagnostics Group (LDG), effective immediately.
Wednesday, December 18, 2013
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Joins Forces with Baylor College of Medicine
Collaboration will see Agilent and Baylor provide customized CGH microarrays for cancer, prenatal and postnatal research.
Thursday, November 14, 2013
Agilent Names Massachusetts Eye and Ear Infirmary as Certified Service Provider for NGS and aCGH Solutions
MEEI's Department of Ophthalmology Ocular Genomics Institute is working to harness the power of genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases.
Thursday, October 24, 2013
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos